Overview

Intranasal Vasopressin Treatment in Children With Autism

Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This purposed of this clinical trial is to investigate the effectiveness of vasopressin nasal spray for treating symptoms associated with autism. Vasopressin is a hormone that is produced naturally within the body and has been implicated in regulating social behaviors. It has been proposed that administration of the hormone may also help improve social functioning in individuals with autism.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Stanford University
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Treatments:
Arginine Vasopressin
Vasopressins